GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.69 (-0.79%)

Growth Price

Undervalued by 89.41%

Stability Price

Overvalued by 40.67%

Company Metrics

  • P/E 7.39
  • P/S 3.54
  • P/B 8.78
  • EPS 11.71
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.15%
  • Avg. Vol. 9.45M
  • Shares 1.52B
  • Market Cap. 115.27B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Better Buy: Gilead Sciences Inc. vs. Amgen Inc. - Jul 20, 2016
Gilead also invested in some strategic deals. In April, the company announced plans to buy Nimbus Therapeutics' Acetyl-CoA Carboxylase (ACC) inhibitor program for treating non-alcoholic steatohepatitis (NASH) and other liver diseases.
Update on Gilead Sciences Inc. (NASDAQ:GILD) for the day - Twin County News
Adage Capital Partners GP L.L.C. Has $159794000 Stake in Gilead Sciences Inc ...
The Cerbat Gem - Jul 23, 2016
Gilead Sciences logo Adage Capital Partners GP L.L.C. increased its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 17.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC).
Gilead Sciences Inc. (GILD) is Temasek Holdings Private Ltd's 3rd Largest Position - BBNS
Gilead Sciences, Inc.: 2 GILD Stock Trades for Earnings - Nasdaq
Is Gilead Sciences, Inc. Stock A Buy Ahead Of Second Quarter Earnings
Amigobulls - Jul 22, 2016
Gilead announces its own set of numbers on the 25th of July where $3.02 will be the number expected for earnings and a top line number of $7.8 billion.
Company Update (NASDAQ:GILD): Gilead Sciences, Inc. Receives Positive CHMP ...
Smarter Analyst - Jul 22, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency(EMA), has adopted a positive opinion on the company's Type II variation ...
Gilead Gets European CHMP's Positive Opinion On Its Type II Variation ... - Benzinga
European Ad Comm backs pre-exposure prophylaxis labeling for Gilead's HIV med ... - Seeking Alpha
Stock Performance Rundown on Gilead Sciences Inc. (NASDAQ:GILD)
Engelwood Daily - Jul 23, 2016
When speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Gilead Sciences Inc. (NASDAQ:GILD)'s stock has performed at various points in its past. Currently, the ...
Gilead Sciences, Inc. Stock Is Set To Recover 2015 Highs Shortly
Amigobulls - Jul 13, 2016
What I have learned in investing over the years is that if one scales into a position at the wrong time, the end result is always pain no matter how well the initial fundamentals stack up.
Do Gilead Sciences, Inc. (NASDAQ:GILD) and Pfizer Inc. (NYSE:PFE) Have ... - Market Exclusive
Gilead Sciences: Value Play Or Value Trap? - Seeking Alpha
Time To Put On The Watch List? - Gilead Sciences Inc. (NASDAQ:GILD), Heat ...
The Voice Registrar - Jul 21, 2016
Gilead Sciences Inc. (NASDAQ:GILD) share price increased to $86.66 each in the last trading session compared to a prior closing price of $85.44.
HC Stocks Outlines: Gilead Sciences, Inc. (NASDAQ:GILD), Community Health ...
share market updates (press release) - Jul 22, 2016
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) ended Thursday session in green amid volatile trading. The shares closed up +0.58 points or 0.67% at $87.24 with 9.45 million shares getting traded.
Biotech Stocks in New Concerns- Gilead Sciences (NASDAQ:GILD), Adeptus Health ... - Seneca Globe
Gilead 's two phase 3b studies evaluating Odefsey to treat HIV-1 infection ... -
Next Weeks Broker Price Targets For Gilead Sciences, Inc. (NASDAQ:GILD)
Fiscal Standard - 3 hours ago
07/07/2016 - Gilead Sciences, Inc. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 97 price target on the stock.
4 Things To Watch When Gilead Sciences Reports On Monday -
Gilead Sciences Stock Is Poised To Soar Due To New HCV Drug Approval
Amigobulls - Jun 30, 2016
On June 28, Gilead Sciences (NSDQ:GILD) announced that the U.S. Food and Drug Administration had approved Epclusa the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection.
Analysts Shine Light on Gilead Sciences, Inc. (GILD) Following FDA Approval - Smarter Analyst
Two Biotech Stocks Are Just So Hot Right Now: Gilead Sciences Inc. (GILD ... - Zergwatch